Tier 2 — strong

Pilot clinical study to evaluate the anticoagulant activity of fucoidan

Mohammad R Irhimeh, J Helen Fitton, Ray M Lowenthal
Blood Coagulation & Fibrinolysis 2009 20(7):607-610

Bibliography

PubMed
PMID 19696660
DOI
10.1097/MBC.0b013e32833135fe
Funding
Specific funding statement was not available in the bibliographic sources reviewed.
Competing interests
A specific competing-interest statement was not available in the bibliographic sources reviewed. J Helen Fitton has longstanding affiliation with the commercial fucoidan field; this record does not infer an undeclared conflict.

Study snapshot

DesignSingle-blind placebo-controlled pilot clinical trial
ModelHealthy adult volunteers
Sample20 participants (10 fucoidan, 10 placebo)
Intervention3 g/day of 75% fucoidan capsules versus 3 g/day guar-gum placebo
Duration12 days
EndpointsActivated partial thromboplastin time; Thrombin time; Prothrombin time; Antithrombin III; Anti-factor Xa; Platelet indices

What the study showed, in plain terms

This small safety-oriented trial directly examined the anticoagulant question. Oral 3 g/day fucoidan for 12 days produced some laboratory changes but the investigators concluded that oral anticoagulant activity was not obvious, likely because absorption was low. Strong in-vitro anticoagulant activity should therefore not be translated directly into the claim that oral fucoidan acts like a prescription anticoagulant.

Key findings

Some coagulation laboratory values changed during oral dosing.

The authors judged the in-vivo oral anticoagulant effect not obvious.

Fucoidan showed strong anticoagulant activity in vitro.

What this study can and cannot tell us

Very small sample and short duration.

Older formulation with limited characterization relative to modern extracts.

Does not rule out interactions or bleeding risk in anticoagulated patients.

Not a SIRT6 study.

Related papers in the corpus

Tier 2
PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals
Ajla Hodzic Kuerec et al. · GeroScience · 2026

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability